Advertisement


Georgina V. Long, MD, PhD, on BRAF-Mutated Melanoma: Long-Term Follow-up of Adjuvant Dabrafenib Plus Trametinib vs Placebo

2024 ASCO Annual Meeting

Advertisement

Georgina V. Long, MD, PhD, of the Melanoma Institute Australia and The University of Sydney, discusses final results with up to 10 years’ follow-up data of the COMBI-AD study of patients with stage III BRAF-mutated melanoma who received adjuvant dabrafenib plus trametinib (Abstract 9500).



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
COMBI-AD trial is a randomized phase three clinical trial of adjuvant dabrafenib combined with trametinib versus placebo for resected stage three BRAF mutated melanoma. The final analysis, the long-term data and the overall survival data were presented and show a durable and sustained benefit in terms of relapse-free survival when patients received dabrafenib plus trametinib versus placebo. There was a 48% reduction in the risk of recurrence with nearly 10 years of follow-up. In fact, the median follow-up was 100 months for dabrafenib plus trametinib and 82 months for placebo, and the maximum follow-up was 125 months. So when we look at the relapse-free survival and look at the eight-year relapse-free survival landmark, we saw 50% for dabrafenib and trametinib, which was much higher than the 35% we saw for placebo. Again, we saw a sustained and durable improvement in the distant metastasis-free survival with a hazard ratio of 0.56, that's a 44% reduction in the risk of distant metastasis at first recurrence. So therefore, the two major endpoints were statistically significant with confidence intervals that did not cross one demonstrating this durable and sustained impact of adjuvant dabrafenib-trametinib. The overall survival showed a separation of the Kaplan-Meier curves with a 20% reduction in the risk of death from any cause using adjuvant dabrafenib-trametinib versus placebo. This is a hazard ratio of 0.80. However, the confidence interval just nudged over one, 1.01, and the P-value is 0.063 so this was not statistically significant. We will not see an adjuvant trial which has any separation of the Kaplan-Meier curves. So this is substantial for the modern era of melanoma treatments when we know that we can cure patients in the advanced setting to see any separation of the overall survival curves in the stage three setting. What was remarkable is if we looked at the subgroup of V600E, they seem to benefit the most in terms of overall survival. The dabrafenib-trametinib hazard ratio versus placebo was 0.75, that's a 25% risk reduction terms of death using adjuvant dabrafenib and trametinib for those with the V600E and that was 91% of the trial population. However, for V600K, which was a small subgroup, there was a reversal, the placebo arm seemed to do better than dabrafenib-trametinib, but we have to exercise caution with only 40 and 37 patients in each arm for that analysis, but it does suggest that the main benefit seems to be in patients with V600E melanoma. Interestingly, the relapse-free survival benefit with dabrafenib and trametinib was seen for both V600E, and V600K. So it was only the overall survival where we saw really the substantial benefit in the V600E. So what does this mean for the future? It means that we have a treatment that can be used for BRAF V600 mutated patients for adjuvant therapy for resected stage three. There were no irreversible toxicities with this long-term follow-up data, and we saw a sustained and durable impact on the relapse-free survival, the distant metastasis-free survival, and we did see a numerical improvement in the overall survival as well as the melanoma-specific survival, a very important endpoint as we cure more patients with melanoma.

Related Videos

Palliative Care

Joseph A. Greer, PhD, on Lung Cancer: Telehealth vs In-Person Palliative Care

Joseph A. Greer, PhD, of Massachusetts General Hospital and Harvard Medical School, discusses study findings showing the merits of delivering early palliative care via telehealth vs in person to patients with advanced lung cancer. Using telemedicine in this way may potentially improve access to and more broadly disseminate this evidence-based care model (LBA3).

Lung Cancer

Heather Wakelee, MD, on NSCLC: IMpower010 Survival Results After Long-Term Follow-up of Atezolizumab vs Best Supportive Care

Heather Wakelee, MD, of Stanford University Medical Center, discusses phase III findings showing that the disease-free survival benefit with adjuvant atezolizumab continues to translate into a positive overall survival trend vs best supportive care in patients with stage II–IIIA non–small cell lung cancer (NSCLC). These results further support the use of adjuvant atezolizumab in PD-L1–selected populations, according to Dr. Wakelee (LBA8035).

Breast Cancer

Fabrice Andre, MD, PhD, on Breast Cancer: Interim Analysis From DESTINY-Breast07

Fabrice Andre, MD, PhD, of Gustave Roussy and the Université Paris-Saclay, discusses a dose-expansion interim analysis of trastuzumab deruxtecan (T-DXd) monotherapy and T-DXd plus pertuzumab in patients with previously untreated HER2-positive metastatic breast cancer (Abstract 1009).

Gastroesophageal Cancer

Jens Marquardt, MD, and Jens Hoeppner, MD, on Esophageal Cancer: Phase III Findings on Chemotherapy vs Chemoradiation

Jens Marquardt, MD, of the University of Lübeck, and Jens Hoeppner, MD, of the University of Bielefeld, discuss findings from the ESOPEC trial, which showed that perioperative chemotherapy (fluorouracii, leucovorin, oxaliplatin, docetaxel) and surgery improves survival in patients with resectable esophageal adenocarcinoma when compared with neoadjuvant chemoradiation (41.4 Gy plus carboplatin and paclitaxel) followed by surgery (LBA1).

Multiple Myeloma

Claudio Cerchione, MD, PhD, on Staging Multiple Myeloma: New Findings on FDG PET/CT Scans and Whole-Body MRI

Claudio Cerchione, MD, PhD, of Italy’s Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, discusses preliminary findings from a prospective trial suggesting that by adding whole-body MRI to fludeoxyglucose-18 (FDG) PET/CT scans, clinicians may detect bone lesions earlier and more accurately in patients with either newly diagnosed or relapsed multiple myeloma, thus translating into potentially better outcomes (Abstract 7512).

Advertisement

Advertisement




Advertisement